Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference ...

Immatics’ TCR-T cell therapy has secured regenerative medicine advanced therapy designation from the FDA, and the biotech plans to submit a full approval request with the FDA in the first ...

Carisma Therapeutics Inc. and OrthoCellix, a subsidiary of Ocugen, have announced a definitive merger agreement to create a Nasdaq-listed regenerative cell therapy company. The merger, which will ...

Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology ...

Our goal for the past decade has been to make regenerative therapies the highest quality possible along with being the most affordable in the world.”— David Greene, MD, PhD, MBASCOTTSDALE, AZ ...

The cell therapy has been well-tolerated at both dose levels, with no adverse events attributed to NRTX-1001 to date, according to Neurona. The biotech plans to launch other trials for NRTX-1001 ...

A paradigm shift in the way we treat spinal injuries is now in sight, with the world's first regenerative cell therapy being granted approval for a registrational Phase I clinical trial. It's a ...

Age-related immune decline reduces CAR-T cell therapy efficacy. ... "By correcting age-related metabolic defects, we could improve outcomes for a large segment of cancer patients." ...